<DOC>
	<DOCNO>NCT00211549</DOCNO>
	<brief_summary>The purpose study identify dose ( ) IDEA-033 provide meaningful effect treat osteoarthritis knee .</brief_summary>
	<brief_title>An Effectiveness Safety Study IDEA-033 Comparison Oral Naproxen Placebo Treatment Osteoarthritis Knee</brief_title>
	<detailed_description>The objective double-blind , placebo-controlled , randomize study evaluate safety identify dose ( ) IDEA-033 provide minimum clinically meaningful effect treat sign symptom osteoarthritis knee . This study also compare safety profile three dose IDEA-033 treating sign symptom associate osteoarthritis 12 week . The primary hypothesis least one three dose IDEA-033 superior placebo respect three primary efficacy endpoint WOMAC Pain , WOMAC Physical Function , Subject Global Assessment Response Therapy . A second hypothesis increase efficacy increase dos IDEA-033 . Patients receive one five treatment 12 week : Three dos IDEA-033 , naproxen 1 g over-encapsulated tablet + placebo placebo</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Osteoarthritis knee minimum six month Moderate pain involved knee take NSAIDs Must use oral NSAID least three day per week last three month 25 30 day screen Demonstrate xray evidence osteoarthritis involve knee last six month Grade 1 Grade 4 severity involve knee base xray criterion Intraarticular injection arthroscopy involve knee three month Screening visit Inflammation involve knee could relate gout pseudogoutinduced synovitis infection A large bulge effusion History gout pseudogout induce synovitis infection severe knee History partial total knee replacement either knee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Osteoarthritis</keyword>
</DOC>